CSL Limited (ASX:CSL): FY26 Results, Plasma Operations and FY27 Priorities

Aditi Sarkar

26 October 2026 03:57 PM AEDT

CSL Limited (ASX:CSL): FY26 Results, Plasma Operations and FY27 Priorities

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CSL Limited (ASX:CSL) recorded FY26 operating revenue of USD 15.797bn.
Underlying NPATA attributable to shareholders was USD 3.098bn in FY26.
FY26 reported net loss attributable to shareholders was USD 2.579bn, reflecting significant charges.
CSL outlined FY27 priorities across plasma therapies, influenza vaccines and its iron and kidney disease portfolio.

CSL Limited develops and manufactures plasma-derived therapies, influenza vaccines and medicines for iron deficiency and kidney disease through its global biopharmaceutical businesses. Shares in CSL Limited (ASX:CSL) were quoted at AUD 193.42 on 26 October 2026, down 1.67% for the trading session. The company’s FY26 results and subsequent annual report detail restructuring and impairment charges, developments across its three operating divisions and the commercial and manufacturing priorities guiding FY27.

Company Business

CSL Limited (ASX:CSL) operates through CSL Behring, CSL Seqirus and CSL Vifor. CSL Behring supplies therapies for immune deficiencies, bleeding disorders and other rare or serious conditions. Its integrated activities include plasma collection, fractionation, specialist manufacturing and distribution to patients across international markets.

CSL Seqirus develops and manufactures seasonal influenza vaccines and maintains pandemic preparedness capabilities. CSL Vifor operates in iron deficiency and nephrology, with products spanning iron replacement and kidney disease therapies. The group reported operations serving more than 120 countries and employed almost 29,000 people during FY26. Each business faces distinct regulatory, production, pricing and demand conditions.

Recent Development

In its August 2026 full-year results, CSL Limited (ASX:CSL) outlined a transformation program intended to simplify operations, improve manufacturing productivity and focus investment on commercial execution and product development. The group reported USD 176mn in transformation savings realised during FY26, with some savings reinvested into commercial and pipeline activities.

Within CSL Behring, demand for immunoglobulin products continued to support the plasma therapies portfolio, while commercial activity progressed for newer treatments including ANDEMBRY and HEMGENIX. CSL also announced a USD 1.5bn expansion of its manufacturing facility in Kankakee, Illinois, aimed at increasing capacity and improving production efficiency.

CSL Seqirus opened a cell-based influenza vaccine manufacturing facility in Tullamarine, Melbourne. CSL Vifor continued developing its nephrology portfolio, including FILSPARI, while facing competition from generic iron products. The annual report also describes the withdrawal of TAVNEOS in European markets and continuing regulatory engagement in other jurisdictions.

Financial Performance and Sector Context

CSL Limited (ASX:CSL) reported FY26 operating revenue of USD 15.797bn versus USD 15.558bn in FY25. Revenue comprised USD 11.387bn from CSL Behring, USD 2.031bn from CSL Seqirus and USD 2.379bn from CSL Vifor. The group’s underlying NPATA attributable to shareholders was USD 3.098bn, compared with USD 3.219bn in FY25.

The reported net result attributable to CSL shareholders was a loss of USD 2.579bn, against a profit of USD 3.002bn in FY25. The statutory result included USD 7.923bn in restructuring and impairment expenses before tax. These charges distinguish the reported outcome from measures excluding identified one-off costs. Cash flow from operations was USD 3.512bn during FY26, and the company completed an approximately AUD 1bn share buyback.

The sector context differs by segment. Plasma-derived therapies depend on donor collection efficiency, processing capacity and patient access. Influenza vaccine demand is influenced by vaccination rates, public-health purchasing and seasonal product selection. In nephrology and iron therapies, generic competition, regulatory decisions and treatment adoption affect sales and product economics.

Risks to Consider

CSL Limited (ASX:CSL) faces manufacturing execution risks as it invests in capacity and adjusts its operating model. Plasma collection and processing are capital-intensive and require stringent quality controls. Seqirus remains exposed to changes in vaccination uptake, while Vifor faces competition in iron products and regulatory uncertainty around specific treatments. Currency movements, restructuring implementation, product approvals and commercial pricing may also influence results.

What to Watch Next

For CSL Limited (ASX:CSL), FY27 milestones include progress on operational savings, the Kankakee expansion and development of newer plasma and rare-disease therapies. Management expects mid-single-digit constant-currency revenue growth for CSL Behring and low-single-digit growth for CSL Seqirus, while CSL Vifor faces continued challenges from generic iron competition and the European TAVNEOS withdrawal. The scheduled annual general meeting on 27 October 2026 and the next half-year reporting cycle provide further opportunities for operational and financial updates.

Key Insights

CSL’s FY26 disclosures show modest revenue growth alongside a reported loss affected by substantial restructuring and impairment charges. Behring remains the largest revenue contributor, while Seqirus and Vifor operate under different market pressures. Manufacturing investments, transformation execution, commercial adoption and the next financial reporting period are central indicators of progress against the group’s FY27 plans.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.